Prioritizing systemic therapies for genitourinary malignancies: Canadian recommendations during the COVID-19 pandemic
Can Urol Assoc J
.
2020 May;14(5):E154-E158.
doi: 10.5489/cuaj.6595.
Epub 2020 Apr 5.
Authors
Aly-Khan A Lalani
1
,
Kim N Chi
2
,
Daniel Y C Heng
3
,
Christian K Kollmannsberger
2
,
Srikala S Sridhar
4
,
Normand Blais
5
,
Christina Canil
6
,
Piotr Czaykowski
7
,
Sebastien J Hotte
1
,
Nayyer Iqbal
8
,
Denis Soulières
5
,
Dominick Bossé
6
,
Nimira S Alimohamed
3
,
Naveen S Basappa
9
,
Som D Mukherjee
1
,
Eric Winquist
10
,
Lori A Wood
11
,
Scott A North
9
Affiliations
1
Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada.
2
BC Cancer Agency, Vancouver Cancer Center, Vancouver, BC, Canada.
3
Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada.
4
Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
5
Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.
6
The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON, Canada.
7
Cancer Care Manitoba, University of Manitoba, Winnipeg, MB, Canada.
8
Saskatoon Cancer Centre, University of Saskatchewan, Saskatoon, SK, Canada.
9
Cross Cancer Institute, University of Alberta, Edmonton AB, Canada.
10
London Health Sciences Centre, Western University, London, ON, Canada.
11
Queen Elizabeth II Health Sciences Centre, Dalhousie University, Halifax, NS, Canada.
PMID:
32267828
PMCID:
PMC7197961
DOI:
10.5489/cuaj.6595
No abstract available